Bayer is making a big bet on gene therapy with the acquisition of North Carolina-based Asklepios BioPharmaceutical (AskBio).
South Korea’s Celltrion Inc. received emergency use authorization (EUA) from the U.S. Food and Drug Administration for the rapid Covid-19 testing kit Sampinute, which boosted shares of the company and its affiliates.
Alnylam Pharmaceuticals presented complete results from the company’s ILLUMINATE-B Phase III study in children under 6 years with primary hyperoxaluria type 1 (PH1), a rare disorder affecting the kidneys.
San Diego-based Retrophin is buying Orphan Technologies for $90 million in cash up front and up to $427 million in milestone payments.
Shares of Gilead Sciences Inc. rose after the company’s antiviral drug remdesivir became the first approved treatment for Covid-19 in the United States.
Shares of Gilead Sciences jumped in trading following full approval for Veklury (remdesivir) as a treatment for Covid-19.
Walmart Inc. filed a lawsuit against the federal government, seeking clarity on the roles and legal responsibilities of pharmacists and pharmacies in filling opioid prescriptions.
Denmark-based Genmab A/S announced positive topline data from the second part of the Phase III CASSIOPEIA trial evaluating daratumumab (marketed as Darzalex) monotherapy as maintenance treatment compared to observation for patients with newly diagnosed multiple myeloma that are eligible for autologous stem cell transplant.
Thinking like a consumer marketer allows you to discover patients’ mindsets, how they operate daily, and how they move through their lives. This approach can bring a higher level of empathy and authenticity that attracts patients rather than having to chase them. Following these suggestions can help create a patient-centric media strategy that will appeal to your target audience, so they can make better decisions to improve their care and quality of life.
RA Capital Management closed the venture capital firm’s second venture fund at $461 million, aimed at a continued investment strategy into privately held life sciences companies.
